View source for Template:Results of the Women's Health Initiative menopausal hormone therapy randomized controlled trials

{| class="wikitable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}" style="font-size: small; margin-left: auto; margin-right: auto; border: none; text-align:center;"
|+ class="nowrap" | {{Navbar|Results of the Women's Health Initiative menopausal hormone therapy randomized controlled trials|mini=y}} {{Font|size=105%|Results of the <includeonly>{{No selflink|Women's Health Initiative}}</includeonly><noinclude>Women's Health Initiative</noinclude> (WHI) <includeonly>{{No selflink|menopausal hormone therapy}}</includeonly><noinclude>menopausal hormone therapy</noinclude> randomized controlled trials}}
! rowspan="2" | Clinical outcome
! rowspan="2" | Hypothesized <br />effect on risk
! colspan="3" | {{No selflink|Estrogen (medication)|Estrogen}} and {{No selflink|progestogen (medication)|progestogen}}<br />({{abbrlink|CEs|conjugated estrogens}} 0.625&nbsp;mg/day p.o. + {{abbrlink|MPA|medroxyprogesterone acetate}} 2.5&nbsp;mg/day p.o.)<br />(n = 16,608, with uterus, 5.2–5.6 years follow up)
! colspan="3" | {{No selflink|Estrogen (medication)|Estrogen}} alone<br />({{abbrlink|CEs|Conjugated estrogens}} 0.625&nbsp;mg/day p.o.)<br />(n = 10,739, no uterus, 6.8–7.1 years follow up)
|-
! width="100px" | {{Abbrlink|HR|Hazard ratio}}
! width="100px" | 95% {{Abbrlink|CI|Confidence interval}}
! width="100px" | {{Abbrlink|AR|Attributable risk}}
! width="100px" | {{Abbrlink|HR|Hazard ratio}}
! width="100px" | 95% {{Abbrlink|CI|Confidence interval}}
! width="100px | {{Abbrlink|AR|Attributable risk}}
|-
| style="text-align: left;" | [[Coronary heart disease]]
| Decreased
| style="background: #ffcccb;" | 1.24
| 1.00–1.54
| style="background: #ffcccb;" | +6 / 10,000 PYs
| style="background: #cffbd4;" | 0.95
| 0.79–1.15
| style="background: #cffbd4;" | −3 / 10,000 PYs
|-
| style="text-align: left;" | [[Medicine:Stroke|Stroke]]
| Decreased
| style="background: #ffcccb;" | 1.31
| 1.02–1.68
| style="background: #ffcccb;" | +8 / 10,000 PYs
| style="background: #ffcccb;" | 1.37
| 1.09–1.73
| style="background: #ffcccb;" | +12 / 10,000 PYs
|-
| style="text-align: left;" | [[Medicine:Pulmonary embolism|Pulmonary embolism]]
| Increased
| style="background: #ffcccb;" | 2.13
| 1.45–3.11
| style="background: #ffcccb;" | +10 / 10,000 PYs
| style="background: #ffcccb;" | 1.37
| 0.90–2.07
| style="background: #ffcccb;" | +4 / 10,000 PYs
|-
| style="text-align: left;" | [[Venous thromboembolism]]
| Increased
| style="background: #ffcccb;" | 2.06
| 1.57–2.70
| style="background: #ffcccb;" | +18 / 10,000 PYs
| style="background: #ffcccb;" | 1.32
| 0.99–1.75
| style="background: #ffcccb;" | +8 / 10,000 PYs
|-
| style="text-align: left;" | [[Medicine:Breast cancer|Breast cancer]]
| Increased
| style="background: #ffcccb;" | 1.24
| 1.02–1.50
| style="background: #ffcccb;" | +8 / 10,000 PYs
| style="background: #cffbd4;" | 0.80
| 0.62–1.04
| style="background: #cffbd4;" | −6 / 10,000 PYs
|-
| style="text-align: left;" | [[Medicine:Colorectal cancer|Colorectal cancer]]
| Decreased
| style="background: #cffbd4;" | 0.56
| 0.38–0.81
| style="background: #cffbd4;" | −7 / 10,000 PYs
| style="background: #ffcccb;" | 1.08
| 0.75–1.55
| style="background: #ffcccb;" | +1 / 10,000 PYs
|-
| style="text-align: left;" | [[Medicine:Endometrial cancer|Endometrial cancer]]
| –
| style="background: #cffbd4;" | 0.81
| 0.48–1.36
| style="background: #cffbd4;" | −1 / 10,000 PYs
| –
| –
| –
|-
| style="text-align: left;" | [[Medicine:Hip fracture|Hip fracture]]s
| Decreased
| style="background: #cffbd4;" | 0.67
| 0.47–0.96
| style="background: #cffbd4;" | −5 / 10,000 PYs
| style="background: #cffbd4;" | 0.65
| 0.45–0.94
| style="background: #cffbd4;" | −7 / 10,000 PYs
|-
| style="text-align: left;" | Total [[Medicine:Bone fracture|fracture]]s
| Decreased
| style="background: #cffbd4;" | 0.76
| 0.69–0.83
| style="background: #cffbd4;" | −47 / 10,000 PYs
| style="background: #cffbd4;" | 0.71
| 0.64–0.80
| style="background: #cffbd4;" | −53 / 10,000 PYs
|-
| style="text-align: left;" | Total [[Mortality rate|mortality]]
| Decreased
| style="background: #cffbd4;" | 0.98
| 0.82–1.18
| style="background: #cffbd4;" | −1 / 10,000 PYs
| style="background: #ffcccb;" | 1.04
| 0.91–1.12
| style="background: #ffcccb;" | +3 / 10,000 PYs
|-
| style="text-align: left;" | Global index
| –
| style="background: #ffcccb;" | 1.15
| 1.03–1.28
| style="background: #ffcccb;" | +19 / 10,000 PYs
| style="background: #ffcccb;" | 1.01
| 1.09–1.12
| style="background: #ffcccb;" | +2 / 10,000 PYs
|-
| style="text-align: left;" | [[Medicine:Diabetes|Diabetes]]
| –
| style="background: #cffbd4;" | 0.79
| 0.67–0.93
| 
| style="background: #cffbd4;" | 0.88
| 0.77–1.01
|
|-
| style="text-align: left;" | [[Gallbladder disease]]
| Increased
| style="background: #ffcccb;" | 1.59
| 1.28–1.97
| 
| style="background: #ffcccb;" | 1.67
| 1.35–2.06
|
|-
| style="text-align: left;" | [[Stress incontinence]]
| –
| style="background: #ffcccb;" | 1.87
| 1.61–2.18
| 
| style="background: #ffcccb;" | 2.15
| 1.77–2.82
|
|-
| style="text-align: left;" | [[Urge incontinence]]
| –
| style="background: #ffcccb;" | 1.15
| 0.99–1.34
| 
| style="background: #ffcccb;" | 1.32
| 1.10–1.58
|
|-
| style="text-align: left;" | [[Medicine:Peripheral artery disease|Peripheral artery disease]]
| –
| style="background: #cffbd4;" | 0.89
| 0.63–1.25
| 
| style="background: #ffcccb;" | 1.32
| 0.99–1.77
|
|-
| style="text-align: left;" | Probable [[Medicine:Dementia|dementia]]
| Decreased
| style="background: #ffcccb;" | 2.05
| 1.21–3.48
| 
| style="background: #ffcccb;" | 1.49
| 0.83–2.66
|
|-
| colspan="8" style="width: 1px; background-color:#eaecf0; text-align: center;" | '''Abbreviations:''' CEs = [[Biology:Conjugated estrogens|conjugated estrogens]]. MPA = [[Biology:Medroxyprogesterone acetate|medroxyprogesterone acetate]]. p.o. = [[per oral]]. HR = [[Hazard ratio|hazard ratio]]. AR = [[Medicine:Attributable risk|attributable risk]]. PYs = [[person–years]]. CI = [[Confidence interval|confidence interval]].  '''Notes:''' [[Sample size]]s (n) include [[Medicine:Placebo|placebo]] recipients, which were about half of patients. "Global index" is defined for each woman as the time to earliest diagnosis for [[coronary heart disease]], [[Medicine:Stroke|stroke]], [[Medicine:Pulmonary embolism|pulmonary embolism]], [[Medicine:Breast cancer|breast cancer]], [[Medicine:Colorectal cancer|colorectal cancer]], [[Medicine:Endometrial cancer|endometrial cancer]] (estrogen plus progestogen group only), [[Medicine:Hip fracture|hip fracture]]s, and [[Biology:Death|death]] from other causes. '''Sources:''' <noinclude><ref name="pmid18348708">{{cite journal | vauthors = Prentice RL, Anderson GL | title = The women's health initiative: lessons learned | journal = Annu Rev Public Health | volume = 29 | issue = | pages = 131–50 | date = 2008 | pmid = 18348708 | doi = 10.1146/annurev.publhealth.29.020907.090947 | url = }}</ref><ref name="pmid25321418">{{cite journal | vauthors = Prentice RL | title = Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke | journal = Semin. Reprod. Med. | volume = 32 | issue = 6 | pages = 419–25 | date = November 2014 | pmid = 25321418 | pmc = 4212810 | doi = 10.1055/s-0034-1384624 | url = }}</ref><ref name="BassukManson2008">{{cite journal|last1=Bassuk|first1=Shari S.|last2=Manson|first2=JoAnn E.|title=Women's Health Initiative Hormone Therapy Trials|year=2008|doi=10.1002/9780471462422.eoct391}}</ref></noinclude><includeonly>See template.</includeonly>
|}<!--

--><noinclude>{{Documentation|content=
==References==
{{Reflist}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>